Michelsen, BrigitteGeorgiadis, StylianosDi Giuseppe, DanielaLoft, Anne GNissen, Michael JIannone, FlorenzoPombo-Suarez, ManuelMann, HermanRotar, ZigaEklund, Kari KKvien, Tore KSantos, Maria JGudbjornsson, BjornCodreanu, CatalinYilmaz, SemaWallman, Johan KBrahe, Cecilie HMöller, BurkhardFavalli, Ennio GSánchez-Piedra, CarlosNekvindova, LucieTomsic, MatijaTrokovic, NinaKristianslund, Eirik KSantos, HelenaLöve, Thorvardur JIonescu, RuxandraPehlivan, YavuzJones, Gareth Tvan der Horst-Bruinsma, IreneØrnbjerg, Lykke MØstergaard, MikkelHetland, Merete L2022-08-102022-08-102022-07-01Michelsen, B, Georgiadis, S, Di Giuseppe, D, Loft, A G, Nissen, M J, Iannone, F, Pombo-Suarez, M, Mann, H, Rotar, Z, Eklund, K K, Kvien, T K, Santos, M J, Gudbjornsson, B, Codreanu, C, Yilmaz, S, Wallman, J K, Brahe, C H, Möller, B, Favalli, E G, Sánchez-Piedra, C, Nekvindova, L, Tomsic, M, Trokovic, N, Kristianslund, E K, Santos, H, Löve, T J, Ionescu, R, Pehlivan, Y, Jones, G T, van der Horst-Bruinsma, I, Ørnbjerg, L M, Østergaard, M & Hetland, M L 2022, 'Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries', Arthritis Care & Research, vol. 74, no. 7, pp. 1205-1218. https://doi.org/10.1002/acr.245600893-7524Jisc: 4a6ebb9610b74e44960bb2dbc2171be8ORCID: /0000-0003-0016-7591/work/101050628https://hdl.handle.net/2164/19053ROLE OF THE STUDY SPONSOR Novartis had no role in the study design or in the collection, analysis, or interpretation of the data, the writing of the manuscript, or the decision to submit the manuscript for publication. Publication of this article was not contingent upon approval by Novartis14847704engR MedicineRJournal article10.1002/acr.24560747